Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Update
by Doug Wharley · The Cerbat GemAethlon Medical, Inc. (NASDAQ:AEMD – Get Free Report) saw a large growth in short interest in the month of May. As of May 15th, there was short interest totaling 28,844 shares, a growth of 105.3% from the April 30th total of 14,050 shares. Currently, 1.9% of the shares of the company are short sold. Based on an average daily volume of 59,037 shares, the short-interest ratio is presently 0.5 days.
Aethlon Medical Price Performance
NASDAQ:AEMD traded down $0.21 during trading hours on Tuesday, reaching $2.20. The company had a trading volume of 554,832 shares, compared to its average volume of 1,553,136. Aethlon Medical has a 1-year low of $1.36 and a 1-year high of $30.40. The firm has a market cap of $3.45 million, a PE ratio of -0.15 and a beta of 1.49. The business’s 50 day moving average price is $2.25 and its 200-day moving average price is $2.60.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC acquired a new stake in shares of Aethlon Medical, Inc. (NASDAQ:AEMD – Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical as of its most recent SEC filing. 1.99% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a report on Monday, April 20th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce”.
Get Our Latest Analysis on Aethlon Medical
About Aethlon Medical
Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.
The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.